Neoadjuvant Radiotherapy and Capecitabine With or Without Panitumumab in Patients With Advanced, K-Ras Unmutated Rectal Cancer. A Randomized Multicenter Phase II Trial.

Trial Profile

Neoadjuvant Radiotherapy and Capecitabine With or Without Panitumumab in Patients With Advanced, K-Ras Unmutated Rectal Cancer. A Randomized Multicenter Phase II Trial.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2015

At a glance

  • Drugs Panitumumab (Primary) ; Capecitabine
  • Indications Rectal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 27 Jun 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
    • 27 Jun 2012 Planned End Date 1 Dec 2013 added as reported by ClinicalTrials.gov.
    • 25 Jun 2011 Results presented at the 13th World Congress on Gastrointestinal Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top